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To	 address	 the	 uncertainty	 of	 the	 indirectly	measured	 tu-
berculosis case detection rate, we used survey data strati-
fied	by	HIV	status	 to	calculate	 the	patient	diagnostic	 rate,	
a directly measurable indicator, in 8 communities in South 
Africa.	 Rates	 were	 lower	 among	 HIV-negative	 than	 HIV-
positive	 persons.	Tuberculosis	 programs	 should	 focus	 on	
HIV-negative	persons.	
The accuracy of the indirectly measured tuberculosis (TB) case detection rate is uncertain. A directly mea-
surable indicator for TB case detection has been proposed 
(1) and subsequently used in analyses (2,3) from prevalence 
surveys. This indicator, the patient diagnostic rate (PDR), is 
defined as the rate at which prevalent case-patients are re-
cruited by TB programs (1). It is estimated by dividing the 
notification rate (number of newly notified cases/100,000 
population/year) by the prevalence (number of all new 
cases/100,000 population). To focus TB program efforts for 
case detection, PDR can be stratified by patient variables 
such as smear positivity, age, sex, and HIV status. To inves-
tigate differences in the rate at which cases are detected, we 
used data from the Zambia South Africa Tuberculosis and 
AIDS Reduction (ZAMSTAR) trial (4) prevalence survey. 
Before beginning the study, we obtained approval from the 
Health Research Ethics Committees of Stellenbosch Uni-
versity, the University of Zambia, and the London School 
of Hygiene and Tropical Medicine.
The Study
The 2010 ZAMSTAR survey measured prevalence of cul-
ture-positive TB after 3 years of interventions in communi-
ties with a high TB/HIV burden. We selected communities 
that had a TB notification rate of >400 cases/100,000 popu-
lation/year, were served by a healthcare facility offering 
TB diagnosis and treatment, and had a catchment area of 
>25,000 persons. Standard census enumerator areas were 
randomly selected within communities, and all adults (>18 
years of age) from all households within the selected areas 
were asked to participate.
After obtaining written informed consent, we collected 
1 sputum sample from each adult and offered HIV testing 
with 2 rapid HIV tests (Determine HIV-1/2, Alere, San 
Diego, CA, USA; and Uni-Gold, Trinity Biotech, Bray, 
Ireland). Participants who self-reported themselves as HIV 
positive were asked to be retested, but if they refused, they 
were not tested and were assumed to be HIV positive. Spu-
tum samples were inoculated onto manual mycobacterial 
growth indicator tubes (Becton Dickinson, Franklin Lakes, 
NJ, USA), and identification of Mycobacterium tubercu-
losis isolates was confirmed by 16SrRNA sequencing (4).
Community notification rates were determined by us-
ing 2010 notification data from the electronic TB register of 
the community facility for the number of all newly notified 
cases (numerator) and 2011 census data for the estimated 
population size (denominator). To estimate the number of 
persons living with HIV, we stratified notification rates by 
using HIV data from the TB register for notified cases and 
by splitting the population per community into HIV posi-
tive or negative according to prevalence survey HIV re-
sults (Table 1). Prevalence rates were standardized by age 
and sex according to the 2011 census age/sex distribution 
per community. Prevalence data were stratified by HIV 
by using a survey variable that captured HIV test results 
combined with self-reported HIV status (online Techni-
cal Appendix, http://wwwnc.cdc.gov/EID/article/22/3/15-
1618-Techapp1.pdf). The PDR per community, stratified 
by HIV status, was calculated by dividing notification rate 
by prevalence (Table 2).
We assumed that the 2011 census would give an accu-
rate estimate of the community population in 2010 and that 
the HIV prevalence in the community population would be 
similar to that in the survey population. We varied these 
assumptions according to estimated national population 
growth and national adult HIV prevalence in a sensitivity 
analysis; the effect was minimal (data not shown).
Overall, the PDR was 0.34 (95% CI 0.29–0.39) per 
person-year for the HIV-negative population and 1.53 (95% 
CI 1.27–1.79) per person-year for the HIV-positive popula-
tion. In all 8 communities, the PDR was lower for the HIV-
negative than the HIV-positive population (Table 2).
Study limitations included selection bias, which could 
have been introduced by sampling of areas with high 
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notification rates. High notification rates could indicate 
a well-functioning reporting system, in contrast to areas 
with lower notification rates and possibly poorer reporting 
systems where similar prevalence rates could have been 
obtained. Similar prevalence rates with lower notification 
rates would have further decreased PDR. The uncertainty 
around HIV prevalence was not accounted for in the analy-
sis. HIV status of survey participants combined self-report-
ed data and HIV tests performed as part of the survey, but 
HIV status for a large number of participants remained un-
known. Accurate data would have narrowed the 95% CIs. 
HIV results were sometimes missing from notification data, 
but unknown HIV status was not included in the analysis. 
HIV status information was missing specifically for 1 of 
the 8 communities (community B) and could have biased 
the results if a higher proportion of missing results were for 
HIV-positive and TB-negative persons, which would have 
meant a lower TB prevalence in the HIV-positive group 
and therefore a higher PDR. Few TB cases were diagnosed, 
leading to a small sample size, especially when the number 
of missing HIV results was considered. The assumption 
that the community size and age/sex distribution was the 
same in 2010 as in the 2011 census could have influenced 
the results.
Conclusions 
In the absence of HIV infection, a PDR of >0.84 per per-
son-year corresponds to the World Health Organization 
goal of detecting >70% incident cases according to the 
original Styblo model (5), assuming a disease duration of 2 
years. However, when taking HIV status into account, dis-
ease durations of 3 years for HIV-negative and 0.93 years 
for HIV-positive persons are assumed (6), meaning that a 
case detection rate of >70% would correspond to a PDR of 
0.78 among HIV-negative and 2.51 among HIV-positive 
persons. Our analysis showed that TB cases were detected 
at a lower rate among HIV-negative than among HIV-
positive persons. None of the communities detected HIV-
negative cases at a sufficient rate to limit transmission. Our 
results are specific to the ZAMSTAR communities in the 
Western Cape, which has many facilities with integrated 
TB/HIV programs and might not be representative of other 
non-ZAMSTAR settings, although TB/HIV integration is 
included in the South African National Tuberculosis Man-
agement Guidelines (http://www.sahivsoc.org/upload/doc-
uments/NTCP_Adult_TB%20Guidelines%2027.5.2014.
pdf). However, our findings are similar to those of a study 
in Kenya (2), indicating that the PDR seems a consistent 
and appropriate statistic for evaluating case detection by 
using prevalence survey data from countries with a high 
burden of TB and HIV. A study of miners in South Africa 
showed that the duration of confirmed TB before diagnosis 
(calculated by dividing point prevalence by incidence) was 
0.80 (95% CI 0.42–1.35) years among HIV-positive and 
2.39 (95% CI 1.37–4.21) years among HIV-negative per-
sons (7). These findings are similar to those of this study. 
Prevalence estimates were used in conjunction with inci-
dence to determine disease duration; we used notification 
rates instead of incidence, in conjunction with prevalence 
estimates, to determine the rate at which TB programs re-
cruit patients.
Case detection efforts should not focus on HIV-pos-
itive persons only, who seek healthcare earlier (8), are 
smear negative (9,10), and contribute less to community 
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Table 1. Tuberculosis	notification	rates	per	ZAMSTAR	community	in	the	Western	Cape	of	South	Africa,	stratified	by	HIV	status,	2010* 
Community Total† 
Population, no. ‡ 
 
Notifications,	no.	(%)§ 
 
Notification	rate¶ 
HIV– HIV+ HIV– HIV+ Missing	HIV	data HIV– HIV+ 
A 22,830 19,791 3,039  191 251 2	(0.5)  9.7 82.6 
B 16,824 14,699 2,125  45 176 43	(16.3)  3.1 82.8 
C 32,342 26,842 5,500  156 303 12	(2.6)  5.8 55.1 
D 20,418 16,910 3,508  63 127 12	(4.9)  3.7 36.2 
E 91,380 77,086 14,294  202 410 33	(5.1)  2.6 28.7 
F 39,357 33,925 5,432  189 319 8	(1.6)  5.6 58.7 
G 34,765 27,812 6,953  276 440 28	(3.8)  9.9 63.3 
H 24,030 19,804 4,226  141 332 12	(2.5)  7.1 78.6 
Total 281,946 236,869 45,077  1,263 2,358 150	(4.0)  5.3 52.3 
*ZAMSTAR,	Zambian	South	African	Tuberculosis	and	AIDS	Reduction	trial;	HIV–,	HIV-negative;	HIV+,	HIV	positive. 
†Split	into	HIV-positive	and	HIV-negative	according	to	ZAMSTAR	proportions. 
‡Total	adult	(>18 years of age) population, data from 2011 census. 
§Data from 2010 electronic tuberculosis register. 
¶Notification	rate	expressed	per	1,000	persons	per	year. 
 
 
 
 
Table 2. Patient	diagnostic	rate	per	ZAMSTAR	community	in	the	
Western	Cape	of	South	Africa,	stratified	by	HIV	status,	2010* 
Community 
Patient diagnostic rate† 
HIV– (95%	CI) HIV+	(95%	CI) 
A 0.74	(0.4–1.09) 1.63	(1.01–2.26) 
B 0.30	(0.14–0.46) 4.16	(0.81–7.51) 
C 0.28	(0.18–0.38) 1.61	(0.67–2.55) 
D 0.27	(0.15–0.38) 0.81	(0.55–1.08) 
E 0.23	(0.12–0.34) 1.09	(0.55–1.62) 
F 0.33	(0.21–0.45) 2.01	(0.83–3.19) 
G 0.61	(0.37–0.86) 2.64 (1.51–3.76) 
H 0.35	(0.24–0.47) 1.99	(1.22–2.76) 
Total 0.34	(0.29–0.39) 1.53	(1.27–1.79) 
*ZAMSTAR,	Zambian	South	African	Tuberculosis	and	AIDS	Reduction	
trial;	HIV–,	HIV-negative;	HIV+,	HIV	positive. 
†Rate at which prevalent case-patients are recruited by tuberculosis 
programs, per person-year, calculated by dividing the notification rate by 
prevalence. 
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transmission (10); efforts should include strategies to de-
tect HIV-negative patients who might contribute propor-
tionally more to community transmission (11) and be ac-
cessing healthcare services already (12). HIV-negative 
persons who are more likely to be smear positive should 
undergo diagnostic testing for TB; for TB-positive persons, 
effective treatment should be started quickly (13). 
Our findings should be validated with analyses from 
other settings. Given the current World Health Organiza-
tion focus on prevalence surveys, data for such analyses 
should be available. To help TB programs to develop active 
case-finding strategies, future research could investigate 
HIV-negative persons who are at risk of having TB and 
being missed by the healthcare system.
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